Dr. Bosch probably was instrumental in making DCVax-L better through his work with Direct by identifying key characteristics of certain activated DCs that could be selected for out of the mix and amplified so as to reduce the amount of tumor needed to make the vaccine. I believe Fraunhofer also utilized their cell selection technology to help optimize L in a way that reduces signaling interference from incomplete or other undesirable cell type activations. Best wishes.